cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Mirati Therapeutics Inc
3 own
11 watching
Current Price
$0
$0.05
(0.13%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,250.93M
52-Week High
52-Week High
101.3
52-Week Low
52-Week Low
35.7
Average Volume
Average Volume
0.04M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,250.93M
icon52-Week High101.3
icon52-Week Low35.7
iconAverage Volume0.04M
iconDividend Yield--
iconP/E Ratio--
What does the Mirati Therapeutics Inc do?
Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company's clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Read More
How much money does Mirati Therapeutics Inc make?
News & Events about Mirati Therapeutics Inc.
Globe Newswire
3 months ago
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Mirati Therapeutics, Inc. (NASDAQ: MRTX) on behalf of the companys long-term investors. The investigation seeks to determine whether Mirati has issued false and misleading statements and/or failed to ...
Zolmax
3 months ago
Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX Get Rating) have received a consensus recommendation of Hold from the seventeen research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have given a hold ...
Ticker Report
4 months ago
Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX Get Rating) have earned an average recommendation of Hold from the seventeen research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, ...
Zolmax
5 months ago
Mirati Therapeutics (NASDAQ:MRTX Get Rating) had its price target cut by Barclays from $169.00 to $90.00 in a research report released on Wednesday, The Fly reports. Several other research firms also recently weighed in on MRTX. B. Riley began coverage on Mirati Therapeutics in a report on ...
PR Newswire
6 months ago
Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study PR Newswire SAN DIEGO, Dec. 2, 2022 Evaluating Investigational Sitravatinib in Combination with Nivolumab for Patients with Non-Squamous Non-Small Cell Lung Cancer...
Frequently Asked Questions
Frequently Asked Questions
What is Mirati Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Mirati Therapeutics Inc shares?
plus_minus_icon
How can I buy Mirati Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Mirati Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Mirati Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Mirati Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Mirati Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Mirati Therapeutics Inc?
plus_minus_icon
What percentage is Mirati Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Mirati Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.05
(0.13%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00